Cantor Fitzgerald Analysts Give NewLink Genetics (NLNK) a $26.00 Price Target
NewLink Genetics (NASDAQ:NLNK) has been assigned a $26.00 price objective by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 205.88% from the stock’s current price.
A number of other research analysts have also issued reports on the stock. Stifel Nicolaus increased their target price on shares of NewLink Genetics from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. ValuEngine lowered shares of NewLink Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Bank of America started coverage on shares of NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 target price on the stock. Jefferies Group decreased their target price on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $23.29.
Shares of NewLink Genetics (NASDAQ NLNK) traded up $0.05 during trading hours on Monday, hitting $8.50. 606,600 shares of the company’s stock were exchanged, compared to its average volume of 1,324,283. NewLink Genetics has a 1 year low of $5.90 and a 1 year high of $25.17. The firm has a market cap of $302.63, a price-to-earnings ratio of -3.48 and a beta of 1.10.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.